Raynaud's phenomenon is accompanied by a positive 'neck test', 'scleroderma' capillary changes in the nailfolds or antinuclear antibodies. Definitive diagnosis may have to be delayed for several years from the onset of Raynaud's phenomenon until definite characteristic skin changes are seen. Ten cases in which an earlier diagnosis of scleroderma was not substantiated are listed. The earlier incorrect diagnosis would have been avoided by use of the methods described in this paper.
Various terms have been used to denote subdivisions of scleroderma. These include acrosclerosis, diffuse scleroderma and CREST. We have used the terms Type 1, Type 2 and Type 3 based on the early extent of the skin sclerosis where Type 1 (limited extent) indicates sclerodactyly only, Type 2 (moderate extent) indicates sclerosis proximal to the metacarpophalangeal joints but excluding the trunk and Type 3 (extensive) indicates diffuse skin sclerosis including the trunk. The clinical value of this simple classification is reviewed and contrasted to other classifications which appear to be poorly defined and of limited use.
Diagnosis of scleroderma
For many years there have been problems with the diagnosis of scleroderma, largely due to the use of this term for two different groups of conditions. On the one hand there are various dermatological conditions characterized by thickened skin, such as morphoea, linear scleroderma, scleroderma en coup de sabre, or sclerodernia with hemiatrophy, and on the other hand there is a systemic disease characterized by symmetrical stiffness of the skin, vascular insufficiency and disturbance of function of various internal organs. This latter disease was designated by Goetz' 'progressive systemic sclerosis', later shortened because it is not persistently progressive, to 'systemic sclerosis'. It is this latter condition which will be considered in more detail, in the light of experience with patients with scleroderma seen over a period of 30 years.
Definition
It is first necessary to define scleroderma. As the cause is not known, it can only be defined in terms of its clinical manifestations. The following definition applies to the patients we regard as suffering from this disease and probably most of those described by recent writers: 'a condition of obscure origin characterized by symmetrical stiffness of the skin, vascular insufficiency and various characteristic forms of systemic involvement'. Commonly accepted features are listed in Table I . Stiffness of the skin during at least one stage of the clinical course is an essential component of the illness. This avoids including patients with some features of scleroderma but without skin sclerosis, which we have placed in a separate category called 'atypical scleroderma'. Our diagnostic criteria are somewhat more liberal than those of the American Rheumatism Association2 There is widespread agreement that scleroderma varies greatly in severity and prognosis and that some system of subdivision is required. The old classification into acrosclerotic and diffuse was helpful in this respect. The current use of CREST is not helpful as CREST features are spread over the whole range of scleroderma and there is no suitable name for non-CREST. The subdivision into Types 1, 2 and 3 according to the early extent of skin involvement has the advantage that these types are easy to define and is useful in prognosis. The presence of anticentromere antibody may also be associated with a good prognosis, but it is not possible to state whether this is a primary factory in prognosis or a secondary factor related to other clinical features.
The scleroderma type is not the only factor in prognosis. Occasionally Type 1 or Type 2 patients have a severe life-shortening manifestation such as severe small bowel involvement, pulmonary hypertension or primary biliary cirrhosis and, on the other hand, a Type 3 patient may sometimes show a remarkable remission. It is thus apparent that prognosis ultimately depends on response to treatment of particular manifestations of the disease and current subdivisions of scleroderma merely act as guidelines for groups of patients rather than precise prognostic indices for the individual. Continued study of clinical and laboratory features is needed in order to establish an improved classification and clinically useful indices of prognosis.
